Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight
Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight
The purpose of this study is to find out if remeron, also called mirtazapine, can help you
 prevent weight loss while on treatment for your cancer. Remeron is currently used to treat
 depression and has not been approved by the Food and Drug Administration for use to treat
 weight loss.
Weight loss in cancer patients can be the result of inadequate intake or absorption of
 nutrients and/or tumor-induced weight loss due to metabolic changes the tumor is creating in
 the body (1). Inadequate intake resulting in a starvation state can simply be the result of
 eating less due to depression, nausea/vomiting, feelings of fullness, and taste changes (2).
 Though not intentional the weight loss caused by these symptoms can be explained and reversed
 by increasing intake of nutrients. Unintentional weight loss induced by the tumor can be
 caused by multiple physiological factors that increase the catabolism of muscle and fat and
 increased nutrient intake alone may not reverse the weight loss. Unintentional weight loss
 can predict a poor prognosis in cancer patients which is most likely due to decreased doses
 of treatment (3-5).

 Usual care for weight loss in cancer patients varies among practitioners and can include
 nutrition counseling by a registered dietitian or by the practitioner themselves. Treatment
 can vary from counseling patients to increase intake of nutrient dense foods to prescribing
 medications in order to improve appetite or mood, to decrease feelings of fullness, or to
 control nausea/vomiting, etc. (6). However, these interventions do not always work. For
 varied reasons not all patients are able to improve their oral intake of food items and in
 patients with tumor induced weight loss increased oral intake does not improve the metabolic
 changes.

 Anti-depressant medications have weight related side effects (7-9). Mirtazapine has been
 shown to have side effects of increased appetite and increased weight in cancer subjects
 studied for use with depression and nausea. (10-13). These results appeared to range from
 changes in appetite to changes seen in metabolic processes such as changes in the cytokine
 system to reduce inflammation seen in cachectic patients. Therefore, using mirtazapine in
 cancer patients even without depression may help to stop unwanted weight loss and increase
 survival by allowing patient to complete prescribed treatment.
Inclusion Criteria:

 1. All patients, 18 years of age or older, with advanced cancer are eligible.

 2. Patients must have lost 10% in the last 6 months

 3. Patients must have a life expectancy of at least 12 weeks.

 4. Patients must have a Zubrod performance status of 0-3.

 5. Patients must sign an informed consent.

 Exclusion Criteria:

 1. Patients with symptomatic brain metastases are excluded from this study.

 2. Pregnant women or nursing mothers are not eligible for this trial. Patients of child
 bearing potential must use adequate contraception.

 3. Patients with severe medical problems such as uncontrolled diabetes mellitus or
 cardiovascular disease or active infections are not eligible for this trial.

 4. Patients with head and neck cancers and GI cancers who have functional problems that
 limits food intake or absorption of nutrients such as partial or complete bowel
 obstructions, and patients with skin cancers (except melanoma) are not eligible

 5. Patients who lost weight on a voluntary diet.

 6. Patients who are already taking an appetite stimulant or other anti-depressant, except
 for SSRI taken in the morning.

 7. Patients who had surgery in the last 6 months